Cas:477489-69-3 2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine manufacturer & supplier

Chemical Name:2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine

CAS.NO:477489-69-3

Synonyms:2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine

Molecular Formula:C₁₆H₁₄ClN₃O₆S₂

Molecular Weight:443.88200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:162.70000

Exact Mass:443.00100

LogP:5.96620

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine Use and application,2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine technical grade,usp/ep/jp grade.

Related News: A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine manufacturer Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine supplier Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine vendor A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 2-(3-Chlorophenyl)-3-[(4-methyl-3,5-dinitrophenyl)sulfonyl]-1,3-t hiazolidine factory A number of UK citizens had trouble reaching the muster point in time for the first flight out because of road blocks and other restrictions in place in Wuhan.